Dong-A ST announced on the 29th that it has applied to the MFDS for the item license of type 2 diabetes complex Sugadapa. Sugadapa is a complex that combines Evogliptin 5mg, the main ingredient of the DPP-4 inhibitor-based diabetes drug Suganon, developed by Dong-A ST, and Dapagliflozin 10mg, the SGLT-2 inhibitor-based drug. DPP-4 inhibitors can control blood sugar without weight gain and hypoglycemic side effects. SGLT-2 inhibitors are known to reduce blood sugar while causing little hypoglycemia, reduce weight and blood pressure, and relieve heart failure.

An official from Dong-A ST said, Sugadapa is expected to improve blood sugar control in diabetics and improve convenience and medication compliance